Evidence map›Paper›PMID 39916387›Full record

ArticleGlia2025

Ibudilast Protects Retinal Bipolar Cells From Excitotoxic Retinal Damage and Activates the mTOR Pathway.

Sumaya Hamadmad, Tyler Heisler-Taylor, Sandeep Goswami, Evan Hawthorn, Sameer Chaurasia, Dena Martini, Diana Summitt, Ali Zatari, Rahaf Shalash, Misha Sohail and 7 more

Abstract read
In one paragraph

Article in Glia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Sumaya HamadmadDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Tyler Heisler-TaylorDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Sandeep GoswamiDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Evan HawthornDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Sameer ChaurasiaDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Dena MartiniDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Diana SummittDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Ali ZatariDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Rahaf ShalashDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Misha SohailDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Elizabeth G UrbanskiDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Kayla BernsteinDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Julie RacineNationwide Children's Hospital, Columbus, Ohio, USA.
Abhay SatoskarDepartment of Pathology, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.
Heithem M El-HodiriDepartment of Neuroscience, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Andy J FischerDepartment of Neuroscience, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
Colleen M CebullaDepartment of Ophthalmology and Visual Sciences, Havener Eye Institute, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.ORCID 0000-0002-5636-4968

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
The Ohio State University Vision Sciences Research Core Program (OSU-VSRCP)P30EY032857 · NEI · OHIO STATE UNIVERSITY · PI Sayoko E Moroi · 2022 to 2026
$3.6M
Characterization of the role of MIF on retinal health and diseaseR01EY032573 · NEI · OHIO STATE UNIVERSITY · PI CEBULLA, COLLEEN MARIE · 2021 to 2025
$2.1M
NCI NIH HHS P30 CA016058NEI NIH HHS P30 EY032857NEI NIH HHS P30EY032857NEI NIH HHS R01 EY032573NEI NIH HHS R01EY032573Ohio Lions Eye Research FoundationResearch to Prevent Blindness New Chair Challenge GrantU.S. Army Medical Research Acquisition Activity W81XWH1810805
6 · The paper itself

Abstract

Ibudilast, an inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE), has been recently shown to have neuroprotective effects in a variety of neurologic diseases. We utilize a chick excitotoxic retinal damage model to investigate ibudilast's potential to protect retinal neurons. Using single cell RNA-sequencing (scRNA-seq), we find that MIF, putative MIF receptors CD74 and CD44, and several PDEs are upregulated in different retinal cells during damage. Intravitreal ibudilast is well tolerated in the eye and causes no evidence of toxicity. Ibudilast effectively protects neurons in the inner nuclear layer from NMDA-induced cell death, restores retinal layer thickness on spectral domain optical coherence tomography (SD-OCT), and preserves retinal neuron function, particularly for the ON bipolar cells, as assessed by electroretinography. PDE inhibition seems essential for ibudilast's neuroprotection, as AV1013, the analogue that lacks PDE inhibitor activity, is ineffective. scRNA-seq analysis reveals upregulation of multiple signaling pathways, including mTOR, in damaged Müller glia (MG) with ibudilast treatment compared to AV1013. Components of mTORC1 and mTORC2 are upregulated in both bipolar cells and MG with ibudilast. The mTOR inhibitor rapamycin blocked accumulation of pS6 but did not reduce TUNEL positive dying cells. Additionally, through ligand-receptor interaction analysis, crosstalk between bipolar cells and MG may be important for neuroprotection. We have identified several paracrine signaling pathways that are known to contribute to cell survival and neuroprotection and might play essential roles in ibudilast function. These findings highlight ibudilast's potential to protect inner retinal neurons during damage and show promise for future clinical translation.

Indexed as

Neuroprotective AgentsPyridinesRetinal Bipolar CellsTOR Serine-Threonine KinasesAnimalsIndolizinesN-MethylaspartatePyrazolesRetinaSignal TransductionibudilastIndolizinesNeuroprotective AgentsN-MethylaspartatePyrazolesPyridinesTOR Serine-Threonine KinasesIbudilastmTORMüller gliaNMDAretinaretinal neuroprotectionscRNA‐seq

Identifiers

PMID39916387
PMCPMC11920683

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.